Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.

Lee JH, Saw RP, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch J, Howle J, Menzies AM, Carlino MS, Kefford RF, Long GV, Scolyer RA, Rizos H.

Ann Oncol. 2019 Mar 12. pii: mdz075. doi: 10.1093/annonc/mdz075. [Epub ahead of print]

PMID:
30860590
2.

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.

Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R.

Ann Oncol. 2018 Feb 1;29(2):490-496. doi: 10.1093/annonc/mdx717.

3.

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ.

Ann Oncol. 2019 Feb 6. pii: mdz048. doi: 10.1093/annonc/mdz048. [Epub ahead of print]

PMID:
30838379
4.

Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.

Hoshimoto S, Shingai T, Morton DL, Kuo C, Faries MB, Chong K, Elashoff D, Wang HJ, Elashoff RM, Hoon DS.

J Clin Oncol. 2012 Nov 1;30(31):3819-26. doi: 10.1200/JCO.2011.40.0887. Epub 2012 Sep 24.

5.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H.

Ann Oncol. 2017 May 1;28(5):1130-1136. doi: 10.1093/annonc/mdx026.

PMID:
28327969
6.

Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients.

Crookes TR, Scolyer RA, Lo S, Drummond M, Spillane AJ.

Ann Surg Oncol. 2017 May;24(5):1378-1385. doi: 10.1245/s10434-016-5723-0. Epub 2017 Jan 27.

PMID:
28130620
7.

Interferon alpha for the adjuvant treatment of cutaneous melanoma.

Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V.

Cochrane Database Syst Rev. 2013 Jun 18;(6):CD008955. doi: 10.1002/14651858.CD008955.pub2. Review.

PMID:
23775773
8.

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A.

Lancet Oncol. 2015 May;16(5):522-30. doi: 10.1016/S1470-2045(15)70122-1. Epub 2015 Mar 31. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262. Lancet Oncol. 2016 Jun;17 (6):e223.

PMID:
25840693
9.

The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis.

Rossi CR, Mozzillo N, Maurichi A, Pasquali S, Quaglino P, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Mocellin S, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M.

Ann Oncol. 2014 Jan;25(1):240-6. doi: 10.1093/annonc/mdt510.

10.

Limitations of lymph node ratio, evidence-based benchmarks, and the importance of a thorough lymph node dissection in melanoma.

Grotz TE, Huebner M, Pockaj BA, Perkins S, Jakub JW.

Ann Surg Oncol. 2013 Dec;20(13):4370-7. doi: 10.1245/s10434-013-3186-0. Epub 2013 Sep 18.

PMID:
24046102
11.

Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.

Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang HJ, Elashoff R, Mozzillo N, Kelley MC, Thompson JF, Lee JE, Hoon DS.

Ann Surg. 2012 Feb;255(2):357-62. doi: 10.1097/SLA.0b013e3182380f56.

12.

Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.

Chang GA, Tadepalli JS, Shao Y, Zhang Y, Weiss S, Robinson E, Spittle C, Furtado M, Shelton DN, Karlin-Neumann G, Pavlick A, Osman I, Polsky D.

Mol Oncol. 2016 Jan;10(1):157-65. doi: 10.1016/j.molonc.2015.09.005. Epub 2015 Sep 25.

13.

Prognostic Significance of Nodal Location and Ratio in Stage IIIC Endometrial Carcinoma Among a Multi-Institutional Academic Collaboration.

Mayadev J, Elshaikh MA, Christie A, Nagel C, Kennedy V, Khan N, Lea J, Ghanem A, Miller D, Xie XJ, Folkert M, Albuquerque K.

Am J Clin Oncol. 2018 Dec;41(12):1220-1224. doi: 10.1097/COC.0000000000000450.

PMID:
29683799
14.

Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.

Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN.

Cancer. 2008 May 1;112(9):2030-7. doi: 10.1002/cncr.23399.

15.

Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.

Huang SK, Hoon DS.

Mol Oncol. 2016 Mar;10(3):450-63. doi: 10.1016/j.molonc.2015.12.008. Epub 2015 Dec 17. Review.

16.

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting.

Rowe SP, Luber B, Makell M, Brothers P, Santmyer J, Schollenberger MD, Quinn H, Edelstein DL, Jones FS, Bleich KB, Sharfman WH, Lipson EJ.

Mol Oncol. 2018 Oct;12(10):1661-1672. doi: 10.1002/1878-0261.12373. Epub 2018 Sep 8.

17.

Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.

Haydu LE, Scolyer RA, Lo S, Quinn MJ, Saw RPM, Shannon KF, Spillane AJ, Stretch JR, McCarthy WH, Thompson JF.

J Clin Oncol. 2017 May 20;35(15):1721-1729. doi: 10.1200/JCO.2016.71.9393. Epub 2017 Apr 4.

PMID:
28375785
18.

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.

Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour AP, Soyer HP, Garbe C, Herington A, Pollock PM, Hayward NK.

EBioMedicine. 2015 May 12;2(7):671-80. doi: 10.1016/j.ebiom.2015.05.011. eCollection 2015 Jul.

19.

Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.

Nowecki ZI, Rutkowski P, Kulik J, Siedlecki JA, Ruka W.

Br J Dermatol. 2008 Sep;159(3):597-605. doi: 10.1111/j.1365-2133.2008.08710.x. Epub 2008 Jul 4.

PMID:
18616789
20.

Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma.

Bidard FC, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, Cassoux N, Desjardins L, Milder M, Vaucher I, Pierga JY, Lebofsky R, Stern MH, Lantz O.

Int J Cancer. 2014 Mar 1;134(5):1207-13. doi: 10.1002/ijc.28436. Epub 2013 Sep 3.

Supplemental Content

Support Center